The impact of FDA’s new focus on ensuring clinical trials include broader populations may be unknown at the moment, but CDER’s Robert Temple does not think it will create havoc for sponsors.
FDA late last year issued a new Manual of Policies and Procedures (MaPP) document emphasizing that broad clinical...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?